Review
Medicine, General & Internal
Jia Wang, Wenwei Li, Mengting Li, Hanbiao Wu, Zhikun Qiu
Summary: Adjuvant atypical antipsychotics have significant efficacy in the treatment of major depressive disorder patients with inadequate response to antidepressants, but the risks and benefits need to be balanced.
Review
Clinical Neurology
Beatriz Corte-Real, Rodrigo Saraiva, Catarina Rodrigues Cordeiro, Benicio N. Frey, Flavio Kapczinski, Taiane de Azevedo Cardoso
Summary: The study aimed to investigate whether atypical antipsychotics (AA) can induce mania in mood disorders. A systematic review and meta-analysis showed that AA-induced mania is rare and the use of AA is more effective in preventing the development of mania compared to placebo.
JOURNAL OF AFFECTIVE DISORDERS
(2023)
Article
Psychiatry
Enrico Pessina, Azzurra Martini, Fabiola Raffone, Vassilis Martiadis
Summary: This study presents a case-series of treatment resistant unipolar depression patients who showed good response to augmentation with cariprazine after failing to respond to a first augmentation with another atypical antipsychotic. Further studies are needed to confirm these preliminary results.
FRONTIERS IN PSYCHIATRY
(2023)
Article
Clinical Neurology
Yifan Shi, Daihui Peng, Chen Zhang, David Mellor, Huaning Wang, Yiru Fang, Zhiguo Wu
Summary: Objective of this study was to explore the clinical characteristics and symptomatology of major depressive disorder with atypical features based on DSM criteria or only reversed vegetative symptoms. A total of 3187 patients with MDD were enrolled, and the findings supported the validity of DSM defined atypical depression and the clinical utility of the simplified approach of defining atypical features based on only reversed vegetative symptoms.
JOURNAL OF AFFECTIVE DISORDERS
(2023)
Review
Pharmacology & Pharmacy
Akira Nishi, Kyosuke Sawada, Hiroyuki Uchida, Masaru Mimura, Hiroyoshi Takeuchi
Summary: This meta-analysis compared the effectiveness of antipsychotic monotherapy (APM) and placebo in patients with major depressive disorder (MDD). The results showed that APM had higher response and remission rates and greater improvement in depression severity scales compared to placebo. However, placebo had lower study discontinuation rates due to adverse events. Overall, APM may have antidepressant effects in the acute phase of MDD.
PHARMACOPSYCHIATRY
(2023)
Review
Pharmacology & Pharmacy
V. Vadim Tarasov, N. Nikolay Ivanets, A. Andrey Svistunov, N. Vladimir Chubarev, A. Marina Kinkulkina, G. Yuliya Tikhonova, S. Nikita Syzrantsev, V. Ivan Chubarev, Cristian Muresanu, G. Siva Somasundaram, E. Cecil Kirkland, Gjumrakch Aliev
Summary: This review summarizes recent findings in molecular biology and neuroimaging for the classification and identification of depression. While there are currently no reliable biomarkers for the diagnosis of depression types, further research into the molecular mechanisms of different types of depression is promising.
CURRENT PHARMACEUTICAL DESIGN
(2021)
Review
Clinical Neurology
Kody G. Kennedy, Megan Mio, Benjamin I. Goldstein, Paolo Brambilla, Giuseppe Delvecchio
Summary: This review and meta-analysis found that individuals with severe mental illness, especially schizophrenia, have wider retinal venules compared to controls, indicating a potential connection between cerebrovascular health and mental illness.
JOURNAL OF AFFECTIVE DISORDERS
(2023)
Review
Psychiatry
Aleksander Kwasny, Adam Wlodarczyk, Alicja Dywel, Joanna Szarmach, Olivia Strandberg, Wieslaw Jerzy Cubala
Summary: The ultimate goal in MDD treatment is recovery, but some patients still experience residual symptoms such as insomnia, affecting their daily functioning. Residual insomnia, especially mid-nocturnal insomnia, is common in MDD patients and is associated with earlier relapse and poor prognosis. Several non-pharmacological treatments such as CBT-I, MBCT, BA, and pharmacological treatments like gabapentin and clonazepam have proven to be effective in mitigating residual insomnia. CBT-D has limited effectiveness in improving insomnia complaints. More research is needed to explore treatment options and understand different subtypes of insomnia in MDD.
FRONTIERS IN PSYCHIATRY
(2023)
Article
Biochemistry & Molecular Biology
Laura K. M. Han, Richard Dinga, Tim Hahn, Christopher R. K. Ching, Lisa T. Eyler, Lyubomir Aftanas, Moji Aghajani, Andre Aleman, Bernhard T. Baune, Klaus Berger, Ivan Brak, Geraldo Busatto Filho, Angela Carballedo, Colm G. Connolly, Baptiste Couvy-Duchesne, Kathryn R. Cullen, Udo Dannlowski, Christopher G. Davey, Danai Dima, Fabio L. S. Duran, Verena Enneking, Elena Filimonova, Stefan Frenzel, Thomas Frodl, Cynthia H. Y. Fu, Beata R. Godlewska, Ian H. Gotlib, Hans J. Grabe, Nynke A. Groenewold, Dominik Grotegerd, Oliver Gruber, Geoffrey B. Hall, Ben J. Harrison, Sean N. Hatton, Marco Hermesdorf, Ian B. Hickie, Tiffany C. Ho, Norbert Hosten, Andreas Jansen, Claas Kaehler, Tilo Kircher, Bonnie Klimes-Dougan, Bernd Kraemer, Axel Krug, Jim Lagopoulos, Ramona Leenings, Frank P. MacMaster, Glenda MacQueen, Andrew McIntosh, Quinn McLellan, Katie L. McMahon, Sarah E. Medland, Bryon A. Mueller, Benson Mwangi, Evgeny Osipov, Maria J. Portella, Elena Pozzi, Liesbeth Reneman, Jonathan Repple, Pedro G. P. Rosa, Matthew D. Sacchet, Philipp G. Saemann, Knut Schnell, Anouk Schrantee, Egle Simulionyte, Jair C. Soares, Jens Sommer, Dan J. Stein, Olaf Steinstraeter, Lachlan T. Strike, Sophia I. Thomopoulos, Marie-Jose van Tol, Ilya M. Veer, Robert R. J. M. Vermeiren, Henrik Walter, Nic J. A. van der Wee, Steven J. A. van der Werff, Heather Whalley, Nils R. Winter, Katharina Wittfeld, Margaret J. Wright, Mon-Ju Wu, Henry Voelzke, Tony T. Yang, Vasileios Zannias, Greig I. de Zubicaray, Giovana B. Zunta-Soares, Christoph Abe, Martin Alda, Ole A. Andreassen, Erlend Boen, Caterina M. Bonnin, Erick J. Canales-Rodriguez, Dara Cannon, Xavier Caseras, Tiffany M. Chaim-Avancini, Torbjorn Elvsashagen, Pauline Favre, Sonya F. Foley, Janice M. Fullerton, Jose M. Goikolea, Bartholomeus C. M. Haarman, Tomas Hajek, Chantal Henry, Josselin Houenou, Fleur M. Howells, Martin Ingvar, Rayus Kuplicki, Beny Lafer, Mikael Landen, Rodrigo Machado-Vieira, Ulrik F. Malt, Colm McDonald, Philip B. Mitchell, Leila Nabulsi, Maria Concepcion Garcia Otaduy, Bronwyn J. Overs, Mircea Polosan, Edith Pomarol-Clotet, Joaquim Radua, Maria M. Rive, Gloria Roberts, Henricus G. Ruhe, Raymond Salvador, Salvador Sarro, Theodore D. Satterthwaite, Jonathan Savitz, Aart H. Schene, Peter R. Schofield, Mauricio H. Serpa, Kang Sim, Marcio Gerhardt Soeiro-de-Souza, Ashley N. Sutherland, Henk S. Temmingh, Garrett M. Timmons, Anne Uhlmann, Eduard Vieta, Daniel H. Wolf, Marcus V. Zanetti, Neda Jahanshad, Paul M. Thompson, Dick J. Veltman, Brenda W. J. H. Penninx, Andre F. Marquand, James H. Cole, Lianne Schmaal
Summary: Major depressive disorder is associated with increased risk of brain atrophy, aging-related diseases, and mortality. This study found that MDD patients showed a higher brain-predicted age difference compared to controls, but this difference did not seem to be driven by specific clinical characteristics. Subtle patterns of age-related structural brain abnormalities in MDD were observed, highlighting the need for further longitudinal studies to assess the clinical value of these findings.
MOLECULAR PSYCHIATRY
(2021)
Review
Biochemistry & Molecular Biology
Ka Young Kim, Ki Young Shin, Keun-A Chang
Summary: This study focused on major depressive disorder (MDD) and identified potential inflammatory biomarkers associated with suicidal risk. The findings highlighted the significant alterations in peripheral inflammatory factors in MDD patients with suicide-related behaviors, indicating the potential roles of specific biomarkers.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Medicine, General & Internal
David M. Kern, M. Soledad Cepeda, Ruby C. Castilla-Puentes, Adam Savitz, Mila Etropolski
Summary: Patients adding a second-generation antipsychotic (SGA) to their selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI) therapy appeared to have more severe depression and comorbid psychiatric profile than those switching their SSRI/SNRI.
CURRENT MEDICAL RESEARCH AND OPINION
(2021)
Article
Clinical Neurology
Gernot Fugger, Lucie Bartova, Markus Dold, Chiara Fabbri, Giuseppe Fanelli, Raffaella Zanardi, Alexander Kautzky, Joseph Zohar, Daniel Souery, Julien Mendlewicz, Stuart Montgomery, Dan Rujescu, Alessandro Serretti, Siegfried Kasper
Summary: The study found an association between SGA augmentation and the presence of psychotic symptoms, longer lifetime psychiatric hospitalizations, employment of further augmentation strategies with mood-stabilizers and benzodiazepines, and a trend towards higher current suicidal risk in patients with major depressive disorder. However, there was no significant difference in treatment outcome between patients receiving SGA augmentation or AD combination.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2022)
Review
Biochemistry & Molecular Biology
Seok-Won Jeoung, Hyun-Sun Park, Zae Young Ryoo, Dong-Hyung Cho, Hyun-Shik Lee, Hong-Yeoul Ryu
Summary: SUMOylation plays a significant role in maintaining neuronal function in the development of major depressive disorder (MDD).
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Cell Biology
Ana Beatriz Castro Goncalves, Caroline Ferreira Fratelli, Jhon Willatan Saraiva Siqueira, Ligia Canongia de Abreu Cardoso Duarte, Aline Ribeiro Barros, Isabella Possatti, Mauricio Lima dos Santos, Calliandra Maria de Souza Silva, Izabel Cristina Rodrigues da Silva
Summary: This systematic review investigates the influence of MAOA uVNTR polymorphism on MDD and reveals differences in genotypic frequencies between healthy control and MDD groups in different populations, showing consistency across the analyzed articles.
Article
Psychiatry
Ying Xiong, Robert Karlsson, Jie Song, Kaarina Kowalec, Christian Rueck, Robert Sigstroem, Lina Jonsson, Caitlin C. Clements, Evelyn Andersson, Julia Boberg, Cathryn M. Lewis, Patrick F. Sullivan, Mikael Landen, Yi Lu
Summary: This study aims to investigate the genetic overlap between treatment response and resistance in individuals with major depressive disorder (MDD), and provides evidence for the heritability of treatment-related phenotypes. It highlights the overall genetic profile of lithium-sensitivity in treatment-resistant depression (TRD), offering a genetic explanation for the efficacy of lithium in treating TRD.
TRANSLATIONAL PSYCHIATRY
(2023)
Article
Psychology, Clinical
Dimosthenis Tsapekos, Rebecca Strawbridge, Matteo Cella, Allan H. Young, Til Wykes
Summary: This study investigated the impact and transfer mechanisms of cognitive remediation (CR) on functional improvement in individuals with bipolar disorder. The results suggest that cognitive gains after CR contribute to functional changes, with psychosocial functioning partially mediating the effect. Cognitive performance after treatment also moderates the effect of CR on goal attainment at follow-up.
PSYCHOLOGICAL MEDICINE
(2023)
Article
Psychiatry
Cynthia H. Y. Fu, Guray Erus, Yong Fan, Mathilde Antoniades, Danilo Arnone, Stephen R. Arnott, Taolin Chen, Ki Sueng Choi, Cherise Chin Fatt, Benicio N. Frey, Vibe G. Frokjaer, Melanie Ganz, Jose Garcia, Beata R. Godlewska, Stefanie Hassel, Keith Ho, Andrew M. McIntosh, Kun Qin, Susan Rotzinger, Matthew D. Sacchet, Jonathan Savitz, Haochang Shou, Ashish Singh, Aleks Stolicyn, Irina Strigo, Stephen C. Strother, Duygu Tosun, Teresa A. Victor, Dongtao Wei, Toby Wise, Rachel D. Woodham, Roland Zahn, Ian M. Anderson, J. F. William Deakin, Boadie W. Dunlop, Rebecca Elliott, Qiyong Gong, Ian H. Gotlib, Catherine J. Harmer, Sidney H. Kennedy, Gitte M. Knudsen, Helen S. Mayberg, Martin P. Paulus, Jiang Qiu, Madhukar H. Trivedi, Heather C. Whalley, Chao-Gan Yan, Allan H. Young, Christos Davatzikos
Summary: In this study, a consortium called "COORDINATE-MDD" was established to define patterns of brain alteration in major depressive disorder (MDD) using neuroanatomical and neurofunctional heterogeneity as dimensions. By harmonizing imaging data and using machine learning methods, the project aims to predict treatment response at the individual level. International datasets from various MDD populations are being shared, and novel predictors of treatment response are being identified and validated externally.
Review
Clinical Neurology
Oliver Pearson, Nora Uglik-Marucha, Kamilla W. Miskowiak, Scott A. Cairney, Ivana Rosenzweig, Allan H. Young, Paul R. A. Stokes
Summary: This systematic review examined the relationship between sleep disturbance and cognitive impairment in mood disorders. The findings indicate a significant association between sleep disturbance and cognitive impairment in people with mood disorders after adjusting for demographic and clinical factors, while no such association was found in healthy participants. These results underscore the need for further research on sleep disturbances and cognitive impairment in people with mood disorders.
JOURNAL OF AFFECTIVE DISORDERS
(2023)
Review
Psychiatry
A. Ratheesh, D. Hett, J. Ramain, E. Wong, L. Berk, P. Conus, M. A. Fristad, T. Goldstein, M. Hillegers, S. Jauhar, L. Kessing, D. J. Miklowitz, G. Murray, J. Scott, M. Tohen, L. N. Yatham, A. H. Young, M. Berk, S. Marwaha
Summary: This systematic review examined the effectiveness of interventions in the early course of bipolar disorder (BD). The findings suggested that lithium use was associated with lower recurrence risk compared to other mood stabilizers, and mood stabilizers were associated with better global functioning compared to antipsychotics in the medium term. Psychological interventions, such as family-focused and cognitive-behavioral interventions, were associated with reduced recurrence risk or improved symptomatic outcomes. Pharmacological interventions were more efficacious when utilized in the earlier stages of illness.
INTERNATIONAL JOURNAL OF BIPOLAR DISORDERS
(2023)
Article
Clinical Neurology
Jonathan P. Rogers, Mark A. Oldham, Gregory Fricchione, Georg Northoff, Jo Ellen Wilson, Stephan C. Mann, Andrew Francis, Angelika Wieck, Lee Elizabeth Wachtel, Glyn Lewis, Sandeep Grover, Dusan Hirjak, Niraj Ahuja, Michael S. Zandi, Allan H. Young, Kevin Fone, Simon Andrews, David Kessler, Tabish Saifee, Siobhan Gee, David S. Baldwin, Anthony S. David
Summary: The British Association for Psychopharmacology has developed an evidence-based consensus guideline on the management of catatonia. The guideline covers the diagnosis, clinical features, and treatment options for catatonia. It emphasizes the need for more randomized controlled trials and prospective cohort studies in this area.
JOURNAL OF PSYCHOPHARMACOLOGY
(2023)
Editorial Material
Biochemistry & Molecular Biology
Sameer Jauhar, Danilo Arnone, David S. Baldwin, Michael Bloomfield, Michael Browning, Anthony J. Cleare, Phillip Corlett, J. F. William Deakin, David Erritzoe, Cynthia Fu, Paolo Fusar-Poli, Guy M. Goodwin, Joseph Hayes, Robert Howard, Oliver D. Howes, Mario F. Juruena, Raymond W. Lam, Stephen M. Lawrie, Hamish McAllister-Williams, Steven Marwaha, David Matuskey, Robert A. McCutcheon, David J. Nutt, Carmine Pariante, Toby Pillinger, Rajiv Radhakrishnan, James Rucker, Sudhakar Selvaraj, Paul Stokes, Rachel Upthegrove, Nefize Yalin, Lakshmi Yatham, Allan H. Young, Roland Zahn, Philip J. Cowen
Summary: A recent umbrella review found no consistent evidence linking serotonin to the pathophysiology of depression. However, we argue that this conclusion is overstated due to methodological weaknesses, selective reporting of data, oversimplification, and errors in the interpretation of neuropsychopharmacological findings. We use the examples of tryptophan depletion and serotonergic molecular imaging, the two most relevant research areas, to support our argument.
MOLECULAR PSYCHIATRY
(2023)
Article
Biochemistry & Molecular Biology
Jiayuan Xu, Nana Liu, Elli Polemiti, Liliana Garcia-Mondragon, Jie Tang, Xiaoxuan Liu, Tristram Lett, Le Yu, Markus M. Noethen, Jianfeng Feng, Chunshui Yu, Andre Marquand, Gunter Schumann
Summary: Analyses of data from the UK Biobank reveal that different urban living environments are associated with affective, anxiety, and emotional instability symptom groups in adults. These associations are mediated by distinct neurological and genetic pathways. Using data from 156,075 participants, researchers found that social deprivation, air pollution, street network, and urban land-use density were positively correlated with affective symptoms. On the other hand, greenness and generous destination accessibility were negatively correlated with anxiety symptoms. The study suggests that urban living environments may influence specific psychiatric symptom groups through different neurobiological pathways.
Review
Psychiatry
Andrea Ulrichsen, Elliot Hampsey, Rosie H. Taylor, Romayne Gadelrab, Rebecca Strawbridge, Allan H. Young
Summary: This study aims to compare various measures of lithium efficacy in treating bipolar disorder. The results show that between half and two-thirds of patients respond well to lithium across different study designs, baseline mood states, study durations, and bipolar disorder subtypes.
Article
Development Studies
Benjamin Jones, Roberto Cardinale
Summary: Fossil fuel subsidy reforms are crucial for sustainable development goals, as fuel subsidies drain government funds and contribute to environmental degradation. However, progress in reducing these subsidies has been uneven due to weak political and social support for higher prices. The affordability of energy has gained significant attention recently, leading to social unrest in response to sustained energy and price inflation. This paper examines the factors that influence societal and political acceptability of fossil fuel subsidy reforms, drawing insights from a range of countries and emphasizing the need for tailored approaches to reform based on each country's unique context.
CLIMATE AND DEVELOPMENT
(2023)
Article
Chemistry, Medicinal
Win Lee Edwin Wong, Chiara Fabbri, Benjamin Laplace, Danyang Li, Roos van Westrhenen, Cathryn M. Lewis, Gavin Stewart Dawe, Allan H. Young
Summary: This study suggests that CYP2C19 genotypes, and consequently metabolic phenotypes, may play a role in determining clinical responses to SSRIs, particularly escitalopram and citalopram. However, further investigation is needed to better understand this relationship.
Editorial Material
Psychiatry
Antje A. T. S. Reinders, Allan H. H. Young, Dick J. J. Veltman
Summary: This editorial summarizes and discusses papers from a themed series of BJPsych Open that aim to unravel the biological correlates of dissociative symptoms with the goal of improving treatment outcomes.
Article
Clinical Neurology
Allan H. Young, Mohamed Abdelghani, Mario F. Juruena, Viktoriya L. Nikolova, Ramin Nilforooshan
Summary: Treatment-resistant depression (TRD) causes significant burden on patients, health services, and society, yet effective treatment options remain limited. In response, an advisory panel of experts convened to develop best practice statements on the use of esketamine nasal spray for TRD, aiming to improve long-term outcomes for this underserved patient population.
NEUROPSYCHIATRIC DISEASE AND TREATMENT
(2023)
Review
Pharmacology & Pharmacy
Michail Kalfas, Rosie H. Taylor, Dimosthenis Tsapekos, Allan H. Young
Summary: Psychedelic therapy has the potential to revolutionize the treatment of treatment-resistant depression (TRD) by maximizing therapeutic benefits and minimizing risks. Psilocybin shows promise as a game-changer in TRD treatment, with initial evidence suggesting a rapid and sustained antidepressant effect. Further studies are needed to explore the mechanisms of action and long-term effects of psychedelics in TRD.
EXPERT OPINION ON PHARMACOTHERAPY
(2023)
Article
Psychiatry
Dimosthenis Tsapekos, Rebecca Strawbridge, Matteo Cella, Kimberley Goldsmith, Michail Kalfas, Rosie H. Taylor, Samuel Swidzinski, Steven Marwaha, Libby Grey, Elizabeth Newton, Julie Shackleton, Paul J. Harrison, Michael Browning, Catherine Harmer, Hannah Hartland, David Cousins, Stephen Barton, Til Wykes, Allan H. Young
Summary: Cognitive remediation (CR) has been shown to be beneficial for patients with bipolar disorder (BD). This study aims to evaluate the efficacy of CR in euthymic patients with BD and explore its mechanisms of action.
Article
Psychology, Clinical
Eshim S. Jami, Megan Pritchard, Hitesh Shetty, Robert Stewart, Allan H. Young, Margaret Heslin
Summary: This study investigates the use of antidepressant and antipsychotic treatment for Psychotic Major Depression (PMD) in clinical practice and examines how treatment profiles correlate with demographic and clinical symptoms. The results showed that combined antidepressant and antipsychotic pharmacotherapy is the most common treatment for PMD in clinical practice, in line with evidence from treatment research.
JOURNAL OF MENTAL HEALTH
(2023)
